Over six months, an opioid medical prescription program in Kitchener-Waterloo, Ontario, reduced the rate of non-fatal overdoses from 48.5 to 3.3 per 100 person-months. This result, published in the International Journal of Drug Policy, demonstrates a sharp decline in non-fatal overdoses, without demonstrating a causal effect on mortality in the short term. The question that the following six months will leave entirely open is that of sustainable stabilization, social integration, addiction recovery, and lasting funding.
The essentials
- In this Kitchener-Waterloo cohort, the proportion reporting a non-fatal overdose fell from 60% to 15% over six months, according to the International Journal of Drug Policy, without definitive causal demonstration.
- The program aims to reduce exposure to the unregulated market through prescriptions and support services, though the study does not isolate the causal effect of each element.
- The reduction in overdoses is real and measurable; addiction, however, remains present in a significant number of participants at the end of the observed period.
- Ontario is among Canadian provinces where the illicit opioid crisis, fueled by fentanyl, has caused mortality to surge since 2016, making this type of program politically and health-wise urgent.
- Public funding for these programs remains fragile, and their expansion to other cities depends on political decisions that are not guaranteed.
The illicit opioid crisis made the status quo untenable
Canada reached a turning point in 2016. That year, synthetic fentanyl began to massively contaminate the black market for opioids. The presence of extremely potent fentanyl in an unpredictable illicit supply sharply increased the risk of overdose and death. Between 2016 and 2023, more than 40,000 Canadians died from opioid poisoning, according to Health Canada. Ontario concentrates a significant share of these deaths, with peaks in medium-sized urban areas—precisely where harm reduction services are less dense than in Toronto or Vancouver.
Kitchener-Waterloo, with 600,000 inhabitants in the technology corridor of southwestern Ontario, illustrates this gap. The region saw its overdose rates climb without having the response infrastructure developed in major metropolitan centers. It was then that the studied program launched. The program had 162 participants at the initial assessment, of whom 100 completed the six-month follow-up.
The program does not seek to treat addiction in the classical sense. It offers something else: providing prescribed opioids at a known dose, administered in a medical setting with social support, to reduce recourse to drugs from the unregulated market. The immediate objective is to reduce exposure to contaminants and the unpredictability of the illicit market. The unpredictability of products, mixtures, and the high potency of fentanyl all contribute to the risk of death.
From 60% to 15%: How controlled prescription affects overdoses
The central data point of the study deserves careful reading. At enrollment, 60% of the 100 followed participants reported at least one non-fatal overdose in the preceding six months. Six months later, this figure had fallen to 15. Translated into an exposure rate, this represents a shift from 48.5 to 3.3 overdoses per 100 person-months, a reduction of more than 90%.
The mechanism is straightforward. When a participant obtains their opioid through a medical prescription, they know what they are consuming: the substance, the dose, the concentration. The high risk stems notably from the potency of fentanyl, unpredictable quantities, and mixtures with other substances. Prescription reduces exposure to this variable for prescribed doses. It does not eliminate physiological dependence, but it can reduce an important risk factor, without eliminating other possible causes of accidental overdose.
Clinical support plays a distinct role. Participants are monitored regularly by health professionals who adjust prescriptions, detect complications, and maintain a therapeutic relationship. This follow-up is what distinguishes a safer supply program from simple distribution. Without it, controlled prescription would remain immediate risk management without any prospect of stabilization.
Participants also have access to social services: housing, food assistance, orientation toward mental health care. These services do not eliminate addiction, but they reduce the isolation that aggravates vulnerability. The program addresses multiple risk factors simultaneously, which partly explains the magnitude of the observed reduction.
Six months of treatment: Limits and gains
Opioid addiction is a chronic disease. The study focuses on non-fatal overdoses and safer supply programs do not require abstinence; it does not directly evaluate addiction recovery. At the end of six months, participants were receiving prescribed opioids and could reduce their use of street drugs; complete cessation is not established for everyone.
This distinction matters for correctly reading the results. The program aims to reduce overdoses and immediate harms; the study observes a decline in non-fatal overdoses. It does not claim to cure. In addiction literature, this corresponds to an approach called harm reduction—a care philosophy that accepts that abstinence is not always the priority objective, and that keeping someone alive and in relationship with the health system is already a clinically significant result.
The tension between harm reduction and the goal of abstinence has structured Canadian political debate for years. Those who see abstinence as the sole horizon view these programs as a form of endorsement of dependence. Harm reduction advocates respond that living people have a better chance of engaging, one day, in a withdrawal process than people who die of an overdose at 35. The Kitchener-Waterloo data do not settle this philosophical debate, but they empirically establish what the program does and what it does not.
The 2030 horizon that some Canadian researchers invoke to evaluate the long-term impact of these programs on mortality, social integration, emergency use, remains conditional. The six months of follow-up available do not allow projection of sustainable trajectories. What the ICES (Institute for Clinical Evaluative Sciences in Ontario) documents in its work on populations benefiting from similar programs suggests that stabilization develops over time, provided funding holds.
Lessons from programs prior to Kitchener-Waterloo
Canada did not invent this model. Switzerland launched its first medical heroin prescription programs in the late 1980s, under pressure from a public health crisis visible in Zurich parks. Thirty years later, the Swiss model is documented by dozens of studies: reduction in crime related to illicit supply, stabilization of participants’ health status, and in a minority of cases, transition to withdrawal treatments.
The Netherlands followed a similar trajectory. The United Kingdom has an established tradition of opioid substitution prescription. Medicalized prescription programs have produced favorable results on certain indicators, but evidence of mortality and infection reduction varies by country, program, and study. These models do not guarantee sustained cessation of dependence in all participants and often require prolonged treatment.
The Kitchener-Waterloo study provides a precise measure in a North American context dominated by synthetic fentanyl, a substance far more potent than heroin and absent from historical European programs. The results suggest an associated decline in non-fatal overdoses in this local cohort over six months, which constitutes a new contribution to the existing body of evidence.
Comparison with Portugal deserves nuance. Portuguese decriminalization is a penal policy, not a medical prescription program. It has reduced stigmatization and facilitated access to care, but in a context of crisis far less severe than the North American fentanyl crisis. The two approaches pursue distinct objectives and can be complementary. Any ambitious health policy quickly hits the obstacle of availability of human resources necessary for its implementation, as shown by published work on retaining health workers.
The political obstacle: Funding what troubles people
Safer supply programs are politically uncomfortable. They ask governments to fund opioid prescriptions for people who will remain dependent, at least in the short and medium term. In an environment where dependence is still largely seen as a moral choice rather than a chronic illness, this position is difficult to defend before an electorate.
Ontario has experienced marked political swings on these questions. The Ford government, in office since 2018, has maintained an ambiguous position: funding certain harm reduction programs while refusing others, such as supervised consumption sites in certain municipalities. Federal funding for projects is limited in time and depends on contribution agreements, whose duration can range from one to five years.
This budgetary precariousness is the main risk for generalizing the results from Kitchener-Waterloo. A program that works but closes for lack of funding only reduces overdoses for the duration of its existence. Participants then return to street supply, with a risk of fatal overdose upon resumption after a period of relative abstinence—unplanned withdrawal is one of the most dangerous moments in the trajectory of people dependent on opioids.
The funding question refers to an economic logic that some program advocates put forward: each non-fatal overdose treated in emergency care costs roughly a thousand dollars according to cited estimates, while hospitalization can cost several thousand dollars; each death leaves behind documentable social and family costs. Safer supply programs entail documentable implementation costs; overdoses and other harms from substance use produce emergencies, hospitalizations, and productivity losses that data document, though the causal effect of the absence of these specific programs must be evaluated separately. This cost-effectiveness argument is real, but it is not enough to move entrenched political positions rooted in a moral view of addiction.
Comparison with other health systems shows that decisions to expand coverage are rarely purely technical decisions: they depend on political coalitions, institutional power dynamics, and dominant narratives about what certain populations do or do not deserve.
Possible applications of these results in other cities
The Kitchener-Waterloo study is not isolated. It is part of a growing body of Canadian data on safer supply programs, data that ICES compiles across Ontario to enable comparisons between populations and intervention models. This population-based research work is precisely what was missing to move controlled medical prescription from the status of local experimentation to that of evidence-based public health policy.
Several Canadian cities—Halifax, Calgary, Saskatoon—have launched or are considering similar programs, drawing on protocols developed in British Columbia and Ontario. The transferability of the model depends less on city size than on two conditions: a primary care network capable of integrating opioid prescription into regular medical follow-up, and sufficient social services to maintain connection with the most precarious participants.
These conditions are not always met. Rural areas in particular face cumulative obstacles: few physicians trained in addiction treatment, under-resourced social services, stronger stigmatization in smaller communities. Geographic expansion of safer supply programs beyond medium and large cities remains the next challenge. Organizations like the Canadian Addiction Counsellors Association advocate for mobile and decentralized models—prescriptions managed remotely, distribution through varied contact points—whose effectiveness remains to be documented in studies comparable to Kitchener-Waterloo.
What current results allow one to assert is delimited but solid: in this cohort of 100 participants followed for six months, the program was associated with a sharp decline in non-fatal overdoses. This is sufficient to justify cautious expansion and continued evaluation. How far this model can go, toward which populations, which territories, which time horizons, depends on studies to come and the political decisions that follow.
Sources
- International Journal of Drug Policy, Study of the safer supply program in Kitchener-Waterloo: https://pubmed.ncbi.nlm.nih.gov/41456366/
- Health Canada, Data on substance-related harms from opioids and stimulants in Canada: https://health-infobase.canada.ca/substance-related-harms/opioids-stimulants/
- ICES (Institute for Clinical Evaluative Sciences in Ontario), Research on safer opioid supply: https://www.ices.on.ca/impact-stories/advancing-evidence-for-safer-opioid-supply-through-population%E2%80%91based-research/
